<DOC>
	<DOCNO>NCT02723981</DOCNO>
	<brief_summary>Prospective , multi-centre , randomize , open-label , parallel comparison evaluate - incidence bleeding ( COSTA-Bleed ) - incidence ischemic bleeding event ( COSTA-Outcome ) follow therapy abluminal sirolimus coat bio-engineered stent ( COMBO stent ) association short-term single antiplatelet therapy compare guidelines-based strategy patient coronary artery disease indication chronic oral anticoagulant therapy .</brief_summary>
	<brief_title>COMBO-Stent Patients Chronic Anticoagulant Therapy ( COSTA ) COSTA-Bleed COSTA-Outcome Trials</brief_title>
	<detailed_description>The COSTA trial investigator-initiated study aim compare clinical outcome percutaneous coronary intervention ( PCI ) use COMBO-stent base strategy associate short-term antiplatelet therapy guidelines-based therapy patient indication chronic oral anticoagulation . The study organize national , multi-centre prospective , randomized trial . The duration follow-up 15 month .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age 18 older ; Willingness comply study protocol ; subject legally authorize representative must provide write informed consent prior study related procedure , accordance International Conference harmonization Good Clinical Practice ( ICHGCP ) guideline per site requirement . Patients anticoagulant therapy treatmentnaive patient indication chronic anticoagulant therapy . Indications oral anticoagulation may include atrial fibrillation , prosthetic valve disease , peripheral bypass surgery , lung embolism deep vein thrombosis indication accord InvestigatorÂ´s opinion . Single multiple de novo lesion native coronary artery , amenable treatment COMBO stent ; Patients , Investigator 's opinion , treat ( N ) OAC . These may include , instance : history BARC 35 bleed &lt; 12 month ; patient haemorrhagic disorder bleed diathesis ( e.g . von Willebrand disease , haemophilia A B hereditary bleeding disorder , history spontaneous intraarticular bleeding , history prolong bleed surgery/intervention ) ; patient recent major surgery ; history intraocular , spinal , retroperitoneal , intraarticular recent gastrointestinal bleeding unless causative factor permanently eliminate repair ; ( reduction haemoglobin level least 2g/dL , transfusion least two unit blood , symptomatic bleed critical area organ ) include lifethreatening bleeding episode ( symptomatic intracranial bleeding , bleed decrease haemoglobin level least 5g/dL bleed require transfusion least 4 unit blood inotropic agent necessitate surgery ) ; Anaemia ( haemoglobin &lt; 10g/dL ) thrombocytopenia include heparininduced thrombocytopenia ( platelet count &lt; 100E9/L ) screening ; Pregnant nursing patient . Female patient childbearing potential must negative pregnancy test do within 7 day prior index procedure per site standard test ; Other medical illness life expectancy &lt; 2 year ( e.g . know malignancy ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol confound data interpretation associate limited life expectancy ; Patient receive organ transplant wait list organ transplant ; Known hypersensitivity contraindication antiplatelet anticoagulant agent allow guidelinescompliant therapy adequately premedicated ; Previously receive murine therapeutic antibody exhibit sensitization production Human AntiMurine Antibodies ( HAMA ) ; Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study ; Current participation another investigational drug device study except noninterventional registry ; Patients willing able comply protocol requirement consider unreliable Investigator concerning requirement follow study and/or compliance study drug administration ; Angiographic exclusion criterion : Vessel diameter &lt; 2 und &gt; 5mm ; Target lesion characteristic make unsuitable stent delivery deployment ; Planned use stent another coronary device another session ( target vessel nontarget vessel ) , preclude COMBOonly strategy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stent , COMBO Stent , anticoagulation</keyword>
</DOC>